Background
==========

Colorectal cancer incidence and mortality rates are still rising rapidly. It is expected that by 2030, global burden will increase by 60% with 2.2 million new incidences and 1.1 million deaths especially in developing countries rather than developed countries ([@B2]).

Epigenetic alterations are contributed in the pathogenesis, molecular heterogeneity, and progression of CRC disease ([@B36]). The best characterized epigenetic modification is DNA methylation which is a covalent addition of a methyl group (CH3--), obtained from S- adenosyl methionine to the 5 position of a cytosine base within CG dinucleotides by DNMTs to form 5-methylcytosine (5mC).

DNMT1, DNMT3A, and DNMT3B have been identified as DNA methylation functional enzymes in eukaryotic cells. DNMT1 is often referred to as the maintenance methyltransferase which is responsible for maintaining pre-existing methylation patterns during DNA replication ([@B28]). Whereas DNMT3A and DNMT3B are the de novo methylation enzymes, and their importance is correlated with the embryogenesis and pathogenesis of cancer cell ([@B58]). The levels of DNMT3B and DNMT3A are often increased in various cancer tissues and cell lines ([@B43]). They cause hypermethylation of promoter CpG-rich regions in a variety of malignancies ([@B59]) and repress transcription in either methylation-dependent manner ([@B32]; [@B41]) or through their histone deacetylase activity ([@B15]). Moreover, DNMT3B has been shown to play a role in leukemia development and maintenance of Leukemia stem cell function ([@B50]). Contrary to their canonical *de novo* methylation role, a series of experiments using DNMT genetic knockout cell lines suggest DNMT1 and DNMT3B cooperate to maintain methylation in human cancers ([@B47]).

Global hypomethylation of the entire genome and hypermethylation of specific CpG sites become one of the characteristics of colon cancer ([@B55]). The hypoxic microenvironment in solid tumors is known to contribute to inappropriate silencing and re-awakening of genes involved in cancer progression through local epigenetic alterations ([@B51]). Global DNA hypomethylation in peripheral blood leukocytes was found to be a potential biomarker for CRC risk ([@B38]) and breast cancer risk ([@B25]). The stability of DNA methylation as molecular marker and its effect on genes expression facilitates its clinical use in early cancer detection, and make it an attractive target to predict the treatment outcome and patients' response to therapy ([@B42]).

Fluoropyrimidine based therapy is the standard treatment for all stages of CRC. The anticancer efficacy of FP- therapy is highly dependent on multiple factors as intracellular folate concentration, DNMTs expression, methylation background of colonic mucosa and silencing of critical FP metabolizing genes ([@B14]). The development of chemoresistance to FP- therapy was reported to be associated with the methylation of DNA of mismatch repair gene and incidence of colorectal recurrence ([@B52]). Tumors methylation phenotypes were correlated with patients' response to chemotherapy and some studies have identified global DNA methylation as an independent marker for survival and response to FP based therapy in CRC patients (Iacopetta, et al., 2008; [@B3]).

Therefore, this study was designed to investigate the impact of global DNA methylation machinery on the clinical outcome of Egyptian CRC patients treated with FP- based therapy.

Patients and Methods
====================

Samples Collection and Lymphocytic Cell Pellet Preparation
----------------------------------------------------------

This is a prospective study of the effect of global DNA methylation on the treatment outcome of CRC patients. Patients included in this study were with confirmed diagnosis of CRC who were enrolled to the National Cancer Institute, Cairo University during the period from February 2014 to December 2014. Whole blood samples were collected from CRC patients at baseline, then after 3 and 6 months of FP based therapy respectively. In addition to 32 whole blood samples were collected from healthy controls that were matched in age and sex. Mononucleated leukocyte cell pellets were isolated by hemolysin buffer (8.46 g ammonium chloride, 1 g potassium bicarbonate and 1 g ethylene diamine disodium salt dissolved in 1 L and the pH = 7--7.2).

Global DNA Extraction and DNA Hydrolysis
----------------------------------------

The whole genomic DNA was extracted from leukocytes by blood DNA preparation and purification Kit (Jena Bioscience, PP 205S, Germany). DNA hydrolysis was performed with triple enzymatic hydrolysis method as described by [@B9]. One μg of extracted genomic DNA was denatured by heating at 100°C for 3 min then chilled on ice. A mixture of ammonium acetate (0.1 M, pH 5.3) and 2 units of nuclease was incubated with the denatured DNA sample at 45°C for 2 h. Ammonium bicarbonate(1 M), venom phosphodiesterase I (0.002 unit) and alkaline phosphatase (0.5 unit) were subsequently added to the mixture and incubation was continued at 37°C for 2 h.

Global DNA Methylation
----------------------

Global genomic DNA methylation level was determined using (LC/MS/MS) adopting the method determined by [@B33]. The LC-MS-MS system consists of Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA, United States), with a quaternary gradient pump (Agilent 1260 infinity), connected with an online vacuum degasser, column oven and autosampler (Agilent 1260 infinity), coupled to a ABSCIEX Q TRAP 3200 mass spectrometer (ABSCIEX, Applied Biosystem, Germany) equipped with an electrospray ionization (ESI) interface. Data acquisition was performed with analyst 4.0 software (ABSCIEX). The quantification of the global contents of 5mC and 2deoxycytosine (2dC) were performed with multiple reaction monitoring (MRM) (AB Sciex software, Germany) where argon gas collision-induced dissociation of 2dC into the ion transitions pair of m/z 228.1 (molecular ion)/112.2 (fragment ion) and dissociation of 5mC into 242.1 (molecular ion)/126.3 (fragment ion). Calibration curves for 5mC and 2dC had increasing amounts from 0 to 100 ng/ml were constructed. The level of 5mC was determined in ng/DNA and 5mC % was calculated by dividing 5mC level to the total cytosine pool as demonstrated in the formula \[5mC/(2dC + 5mC)\] × 100.

RNA Extraction and DNMT3A and DNMT3B Genes Expression
-----------------------------------------------------

Total RNA was extracted from the lymphocytic cell pellet with total RNA purification kit (Direct-zol RNA Kit, Zymo Research, R2050, Germany). Complementary DNA synthesis was performed according to the manufacturer's instructions using Revert Aid First Strand cDNA synthesis kit (Thermo Fisher). Real-time PCR was conducted by Applied Biosystems syber green PCR master mix. Reverse and forward sequences of primer genes of DNMT3A, DNMT3B, and β-actin were purchased from Invitrogen by (Thermo Fisher Scientific, United Kingdom. DNMT3A forward primer was 5′TTATGGGGATCCTGGAGCGG3′ and the reverse primer was 3′TCTCAGCCGTATCACACTCG5, DNMT3B forward primer was 5′CTACACACAGTCCCTGAGACG3′ and the reverse primer was 3′GTGTCGTCTGTGAGGTCGAT5′. Housekeeping gene β-actin forward primer was 5′CCAGAGCAAGAGAGGTATCC3′ and the reverse primer was 3′CTGTGGTGGTGAAGCTGTAG5′. Cycle threshold (CT) values for genes were normalized to the CT values of β-actin (Δ Ct) and gene relative expression was calculated as (2^-ΔCt^).

Statistical Analysis
--------------------

IBM SPSS statistical package version 24 was used in data manipulation. Numeric data explored for normality using Kolmogorov--Smirnov test and Shapiro--Wilk test. Categorical data were expressed as numbers and percentages while numerical data were summarized as medians and interquartile ranges (IQR). Patients were stratified into subgroups according to their clinicopathological and molecular features. More than two subgroups of patients were tested for significance with Kruksil--Wallas test and the pairwise comparison was done by Mann--Whitney. The effect of FP based therapy on global DNA methylation over time (3 and 6 months) was tested by Friedman test. Pairwise comparison of the effect of time was tested by Wilcoxon matched. The correlation between methylated cytosines content and the expression of DNMT genes was tested by Spearman correlation analysis. After 3 years of follow up, OS and EFS of patients were tested by Kaplan and Meier procedure. OS was calculated from the date of diagnosis to the date of death from any cause. Living patients or patients lost to follow-up were censored on the last known alive date. EFS was calculated from the date of resection or neoadjuvant therapy to the date of recurrence, progression or death, which occurred first. EFS for patients who neither progressed, relapsed, nor died, was censored at last assessment prior to loss of follow-up. Significant clinicopathological and molecular variables on patients' survivals were tested for their hazardous effects on either death or progression using multivariate COX proportion hazard model. The hazard ratio indicates the risk of death during the OS time or the risk of progression during the EFS time, in one group of patients who showed the high level of a variable (table variables) compared with the other group which showed the low level of a variable (reference variables). All P-values are two-sided and P-values \< 0.05 were considered significant.

The research protocol was approval by the Institutional Human Research Ethics Committee of NCI, Egypt, number 00004025, and conducted in accordance with the Declaration of Helsinki. A written informed consent was taken from the participated patients and the full clinico- pathological information was recorded from the patients' files.

Results
=======

Patients' Clinicopathological Characters and Treatment Protocol
---------------------------------------------------------------

**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}** illustrates clinicalo- pathological characteristics and the type of treatment received of 102 Egyptian naïve CRC patients. The mean age ± SD of the patients was 45 ± 13.7 while their median was 46 years ranging from 19 to 72 years. The mean ± Standard deviation of age of healthy controls was 39 ± 13.8 and the male: female ratio = 1: 1.6, *P*-value = 0.16. Nearly half of the patients (46%) were ≤45 years with slight male predominance and rectal cancer was diagnosed in 39.2% the patients. Most of the cases had good performance status (ECOG I) while the rest had PS II or III. High initial CEA and CA19.9 levels were recorded in 41.7 and 20.8% of patients, respectively. It was found that about two thirds (63.72%) of the patients had their primary tumor located in the left side while the right side location was encountered in 29.41% and rectal cancer represented 39.2% of all CRC patients. Adenocarcinoma (69.60%), grade II (80.39%) and T3 tumors (63.72%) were the most common pathological subtypes. Thirty-one patients presented with metastatic disease where the liver was the most frequent site followed by the peritoneum then the lung. The treatment protocol was mainly FP based therapy.

CRC Patients Have Global DNA Hypomethylation With Overexpression of DNMTs 3A and B
----------------------------------------------------------------------------------

At baseline, CRC patients showed global DNA hypomethylation in the form of significant decrease in both 5mC level and 5mC % compared to normal healthy control **Figures [1A,B](#F1){ref-type="fig"}**. The median level of 5mC and 5mC % for 102 patients at baseline was 0.55 and 8.02 respectively. On the other hand, a significant overexpression of DNMT3A and DNMT3B was observed in CRC patients compared to healthy control **Figures [1C,D](#F1){ref-type="fig"}**. An inverse correlation of borderline significance was shown between 5mC level and DNMT3A expression (*r* = -0.21 and *P*-value = 0.09), **Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**.

![Global DNA methylation in healthy control and baseline CRC patients. 5mC level **(A)**, 5mC % **(B)**, DNMT3A **(C)**, and DNMT3B **(D)**.](fphar-09-01173-g001){#F1}

FP Therapy Reduced Significantly 5mC Level, 5mC %, and DNMTs Genes Expression
-----------------------------------------------------------------------------

The effect of FP therapy on global DNA methylation and DNMTs gene expression is shown in **Figure [2](#F2){ref-type="fig"}**. After 6 months of FP therapy, 5mC level, 5mC %, DNMT3A, and DNMT3B were significantly reduced than their corresponding baseline levels. After 3 months of FP therapy, DNMT3B was significantly overexpressed by 2.3 folds while 5mC % was significantly down-expressed to 0.79 folds compared to baseline. 5mC % and DNMT3B gene were significantly reduced after 6 months of FP- therapy compared to the level at the third month.

![Change in the median levels of 5mC, 5mC %, DNMT3A and DNMT3B genes after 3 and 6 months of FP therapy normalized to their baseline levels. a is a significant difference of CRC patients treated with FP for 3 and 6 months were compared with their baseline level, *P*-value \< 0.05. b is a significant difference when CRC patients treated with FP for 6 months were compared with their level after 3 months of treatment, *P*-value \< 0.05.](fphar-09-01173-g002){#F2}

5mC Level and 5mC % in Subgroups of CRC Patients
------------------------------------------------

Using the medians for subgroup analysis of our CRC patients at baseline, Mann--Whitney test of significance showed that patients who were \>45 years, males, right-sided location, T2 tumors, grade III, negative lymph nodes, absence of metastasis and stage II have higher 5mC levels. FP therapy significantly reduced the global methylation in patients who had the higher level of 5mC.

Using the pairwise comparison with Wilcoxon matched test of significance, FP therapy significantly reduced 5mC level in CRC patients with T2 tumors after 3 months. While after 6 months of FP therapy, 5mC significantly reduced in patients \> 45 years, males, adenocarcinoma subtype, T2, and T3 tumors. The level of 5mC was significantly reduced after 6 months relative to 3 months of FP therapy in patients with T3 tumors and adenocarcinoma pathological subtype **Table [1](#T1){ref-type="table"}**.

###### 

Global 5mC levels in subgroups of patients at baseline and after treatment with FP therapy.

  Variables                           5mC level (ng/ DNA) in CRC patients   *P*-Value                                                                                  
  ---------------- ------------------ ------------------------------------- ---------------------- ---- -------------------------- ------- --------------------------- -------------
  Age                ≤45              47                                    0.59 (0.30--0.60)      23   0.55 (0.14--1.26)          15      0.53 (0.24--0.85)           0.368
                     \>45             55                                    0.70^∗^ (0.68--2.09)   25   0.46 (0.28--0.71)          17      0.20**^a^** (0.17--0.35)    ***0.011***
                   ***P*- value**                                           ***0.001***                 0.835                              0.054                       
  Sex                Female           47                                    0.45 (0.38--0.70)      20   0.43 (0.15--1.26)          13      0.29 (0.21--0.45)           0.692
                     Male             55                                    0.86^∗^ (0.79--1.83)   28   0.55 (0.28--0.67)          19      0.20**^a^** (0.17--0.45)    ***0.007***
                   ***P*- value**                                           ***0.029***                 0.694                              0.669                       
  CEA level          Normal           46                                    0.59 (0.44--0.74)      5    0.63 (0.43--0.71)          4       0.19 (0.16--0.25)           0.438
                     High             33                                    0.58 (0.44--0.73)      13   0.51 (0.15--1.26)          8       0.25 (0.20--0.45)           0.053
                   ***P*- Value**                                           0.930                       0.416                              0.237                       
  CA19.9 level       Normal           57                                    0.59 (0.44--0.74)      2    0.61 (0.58--0.63)          1       0.17 (0.17--0.17)           NA
                     High             15                                    0.52(0.39--0.65)       17   0.55 (0.28--1.26)          11      0.28 (0.20--0.43)           0.368
                   ***P*- Value**                                           0.959                       0.449                              0.500                       
  Tumor location     Right colon      30                                    0.73^∗^ (0.62--1.04)   15   0.67 (0.17--3.45)          16      0.26 (0.20--0.44)           0.097
                     Left colon       25                                    0.47 (0.35--0.59)      15   0.58 (0.14--0.69)          6       0.20 (0.17--0.28)           0.135
                     Rectum           40                                    0.67 (0.5--0.84)       18   0.46 (0.38--1.26)          10      0.30 (0.15--1.08)           0.189
                   ***P*- value**                                           ***0.006***                 0.295                              0.441                       
  Pathology          Adenocarcinoma   66                                    0.53 (0.43--0.71)      32   0.53 (0.28--0.99)          22      0.21**^ab^** (0.16--0.53)   ***0.030***
                     Mucinous         34                                    0.46 (0.50--0.84)      16   0.29 (0.15--0.81)          10      0.30 (0.28--0.43)           0.368
                   ***P*- value**                                           0.06                        0.342                              0.315                       
  Tumor grade        II               82                                    0.58 (0.44--0.73)      34   0.46 (0.17--0.67)          24      0.30 (0.20--0.60)           0.115
                     III              20                                    0.72^∗^ (0.69--1.15)   14   0.69 (0.15--1.26)          8       0.21 (0.17--0.26)           0.189
                   ***P*- value**                                           ***0.006***                 0.611                              0.281                       
  Tumor size         T2               15                                    1.08^∗^ (0.81--1.35)   12   0.43**^a^** (0.11--0.63)   9       0.22**^a^** (0.17--0.45)    ***0.020***
                     T3               65                                    0.58 (0.44--0.73)      30   0.53 (0.30--1.26)          18      0.21**^ab^** (0.20--0.30)   ***0.011***
                     T4               19                                    0.63 (0.47--0.79)      6    0.55 (0.14--1.26)          5       0.68 (0.28--1.08)           0.368
                   ***P*- value**                                           ***0.008***                 0.291                              0.560                       
  Lymph node         Negative         41                                    0.71^∗^ (0.53--0.89)   26   0.55 (0.16--0.92)          22      0.30 (0.17--0.60)           0.236
                     Positive         39                                    0.54 (0.41--0.68)      22   0.43 (0.17--0.69)          10      0.25 (0.20--0.43)           0.050
                   ***P*- value**                                           ***0.006***                 0.885                      0.920                               
  Metastasis         Negative         71                                    0.67^∗^ (0.50--0.84)   38   0.55 (0.15--1.26)          24      0.28 (0.20--0.60)           0.050
                     Positive         31                                    0.51 (0.38--0.64)      10   0.38 (0.30--0.63)          8       0.24 (0.16--0.30)           0.178
                   ***P*- value**                                           ***0.005***                 0.696                              0.364                       
                     II               32                                    0.71^∗^ (0.53--0.89)   20   0.51 (0.15--0.92)          13      0.20 (0.14--0.60)           0.472
  Stage              III              39                                    0.59 (0.44--0.74)      18   0.58 (0.28--1.26)          11      0.36 (0.21--1.08)           0.097
                     IV               31                                    0.54 (0.41--0.68)      10   0.38 (0.30--0.63)          8       0.24 (0.16--0.30)           0.178
                   **P- value**                                             ***0.019***                 0.825                              0.346                       

Data presented as medians and interquartile range (IQR) of 5mC level (ng/DNA) of CRC patients at baseline and after treatment with FP therapy for 3 and 6 months. Significant

P

\- values were with bold italic font.

∗

superscript is a significant difference (

P

-value \< 0.05) when the two CRC subgroups were compared by Mann--Whitney.

a

Is a significant difference (

P

-value \< 0.05) when the 3 and 6 months treated CRC patients were compared with their baseline by Wilcoxon Matched.

b

Is a significant difference (

P

-value \< 0.05) when the 6 months treated CRC patients were compared with their 3 months level by Wilcoxon Matched. 5mC, 5 methoxy 2 deoxy cytosine; CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; NA, not applicable.

Insignificant differences in 5mC % among the different subgroups of CRC patients prior FP therapy, whereas FP therapy for 6 months caused significant reduction in 5mC % in patients with T2 tumors and negative lymph nodes compared to the baseline and the 3 months level, **Table [2](#T2){ref-type="table"}**.

###### 

Global 5mC% in subgroups of patients at baseline and after treatment with FP based therapy.

  Variables                           5mC % in CRC patients   *P*-value                                                                              
  ---------------- ------------------ ----------------------- ---------------------- ------- ---------------------- ---- --------------------------- -------------
  Age                ≤45              47                      5.15 (2.44--13.49)     23      6.35 (5.92--14.78)     15   5.45 (5.34--5.87)           0.223
                     \>45             55                      8.62 (5.52--4.08)      25      22.67 (9.80--35.70)    17   5.48 (5.02--6.35)           0.097
                   ***P*-value**      0.117                   0.126                  0.602                                                           
  Sex                Female           47                      5.72 (2.44--13.49)     20      6.53 (6.22--14.78)     13   5.68 (3.88--6.11)           0.097
                     Male             55                      8.81 (5.00--21.21)     28      22.67 (9.80--35.70)    19   5.40 (5.02--6.14)           0.223
                   ***P*-value**      0.403                   0.409                  0.831                                                           
  CEA level          Normal           46                      15.44 (11.58--19.30)   5       6.55 (6.15--35.7)      4    5.87 (2.27--6.35)           0.097
                     High             33                      9.58 (7.19--11.98)     13      33.65(10.96--67.23)    8    5.02 (3.11--5.48)           0.368
                   ***P*-value**      0.985                   0.353                  0.408                                                           
  CA19.9 level       Normal           57                      15.21 (11.41--19.01)   2       12.87 (6.5--33.65)     1    5.48 (5.48--5.48)           NA
                     High             15                      9.80 (7.35--12.25)     17      51.47(35.76--67.23)    11   5.02 (4.22--11.02)          0.062
                   ***P*-value**      0.818                   0.080                  0.472                                                           
  Tumor location     Right colon      30                      13.52 (10.14--16.90)   15      22.67 (14.78--33.65)   16   5.34 (5.13--7.45)           0.135
                     Left colon       25                      9.35 (7.01--11.69)     15      20.96 (6.19--51.47)    6    5.11 (4.32--6.22)           0.760
                     Rectum           40                      9.46 (7.10--11.83)     18      8.18 (6.5--10.96)      10   6.25 (6.02--7.88)           0.060
                   ***P*-value**      0.180                   0.350                  0.370                                                           
  Pathology          Adenocarcinoma   66                      10.36 (7.77--12.95)    32      14.78 (9.80--35.70)    22   5.40 (4.07--5.68)           0.05
                     Mucinous         34                      35.15 (10.36--40.94)   16      6.36 (6.15--22.67)     10   6.25 (6.14--6.35)           0.368
                   ***P*-value**      0.350                   0.239                  0.117                                                           
  Tumor grade        II               82                      10.57 (8.43--17.71)    34      10.96 (6.22--35.70)    24   5.48 (5.34--6.14)           0.097
                     III              20                      12.05 (9.04--15.06)    14      10.64(6.21--35.35)     8    5.02 (2.27--6.35)           0.223
                   ***P*-value**      0.796                   0.794                  0.425                                                           
  Tumor size         T2               15                      9.52 (7.14--16.90)     12      22.67 (14.78--67.23)   9    3.86**^ab^** (2.27--5.45)   ***0.029***
                     T3               65                      13.01 (6.76--22.26)    30      10.38 (6.22--35.70)    18   5.48 (5.02--6.35)           0.097
                     T4               19                      8.14 (7.61--19.68)     6       6.35(6.15--6.55)       5    5.87 (3.87--6.87)           0.368
                   ***P*-value**      0.819                   0.230                  0.407                                                           
  Lymph node         Negative         41                      13.52 (10.14--16.90)   26      14.78 (6.55--49.73)    22   5.45**^ab^** (5.02--5.87)   ***0.022***
                     Positive         39                      9.46(7.10--11.83)      22      8.56 (5.92--22.67)     10   6.14 (4.14--7.14)           0.789
                   ***P*-value**      0.350                   0.157                  0.384                                                           
  Metastasis         Negative         71                      8.52 (4.14--16.90)     38      14.78 (6.22--35.70)    24   5.45 (3.11--6.14)           0.050
                     Positive         31                      6.69 (5.27--12.11)     10      8.73 (3.95--39.10)     8    5.48 (5.02--6.35)           0.368
                   ***P*-value**      0.909                   0.695                  0.732                                                           
  Stage              II               32                      13.52 (10.14--16.90)   20      24.22 (9.80--49.73)    13   5.34 (3.11--5.45)           0.097
                     III              39                      9.80 (7.35--12.25)     18      6.55 (6.15--22.67)     11   6.01 (5.87--6.14)           0.368
                     IV               31                      9.80 (7.35--12.25)     10      8.73 (3.95--39.10)     8    5.48 (5.02--6.35)           0.368
                   ***P*-value**      0.706                   0.488                  0.446                                                           

Data presented as medians and interquartile range (IQR) of 5mC% calculated as \[5mC (ng)/(2dC (ng) + 5mC (ng)\]

∗

100\. Significant
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-values were with bold italic font.

∗

Superscript is a significant difference (

P

-value \< 0.05) when two CRC subgroups were compared by Mann--Whitney.

a

Is a significant difference (

P

-value \< 0.05) when the 3 and 6 months treated CRC patients were compared with their baseline by Wilcoxon Matched.

b

Is a significant difference (

P

-value \< 0.05) when the 6 months treated CRC patients were compared with their 3 months level by Wilcoxon Matched. 5mC, 5 methoxy 2 deoxy cytosine; CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; NA, not applicable.

DNMT3A and DNMT3B Genes Expression in Subgroups of CRC Patients
---------------------------------------------------------------

Subgroup analysis of CRC patient after 3 months of FP therapy showed that DNMT3A expression level was significantly high in patients with adenocarcinoma type of tumors and high CA19.9 level. Pairwise comparison, FP therapy revealed that significant induction in DNMT3A gene expression was associated CRC patients with good prognostic features after 3 months of therapy. CRC patients with right colon tumors, adenocarcinoma, negative lymph nodes, negative metastasis and stage II had significant higher 5mC% compared to their baseline after 3 months of FP therapy, **Table [3](#T3){ref-type="table"}**.

###### 

DNMT3A gene expression in subgroups of patients at baseline and after treatment with FP based therapy.

  Variables                           DNMT3A gene expression relative to B- actin (2^-ΔCT)^ in CRC patients   *P*-value                                                                           
  ---------------- ------------------ ----------------------------------------------------------------------- -------------------- ------- --------------------------- ---- --------------------- -------------
  Age                ≤45              47                                                                      1.28 (0.033--3.83)   23      1.26 (0.25--5.33)           15   1.224 (0.009--2.60)   0.150
                     \>45             55                                                                      1.07 (0.10--2.26)    25      2.62 (0.73--4.77)           17   2.003 (0.44--3.76)    0.157
                   ***P*-value**      0.413                                                                   0.964                0.101                                                          
  Sex                Female           47                                                                      0.81 (0.07--2.46)    20      1.26 (0.66--4.58)           13   1.19 (0.15--2.09)     0.246
                     Male             55                                                                      1.20 (0.21--5.07)    28      2.64 (0.25--5.10)           19   2.59 (1.224--7.64)    0.779
                   ***P*-value**      0.269                                                                   0.816                0.150                                                          
  CEA level          Normal           46                                                                      1.03 (0.09--2.469)   5       2.42 (1.20--0.67)           4    1.42 (0.15--3.36)     0.486
                     High             33                                                                      0.55 (0.08--4.59)    13      1.26 (0.19--5.33)           8    1.58 (1.43--7.60)     0.247
                   ***P*-value**      0.905                                                                   0.881                0.670                                                          
  CA19.9 level       Normal           57                                                                      1.03 (0.09--2.94)    2       1.26 (0.35--4.35)           1    1.43 (0.13--4.32)     NA
                     High             15                                                                      0.18 (0.03--6.37)    17      7.79**^∗^** (6.79--63.52)   11   3.27 (2.26--6.07)     0.223
                   ***P*-value**      0.942                                                                   ***0.025***          0.172                                                          
  Tumor location     Right colon      30                                                                      1.15 (0.24--2.94)    15      3.22**^a^** (2.42--5.72)    16   2.60 (0.81--3.35)     ***0.046***
                     Left colon       25                                                                      1.94 (0.29--4.12)    15      1.94 (1.01--3.53)           6    1.22 (0.44--2.26)     0.819
                     Rectum           40                                                                      0.58 (0.04--2.53)    18      0.49 (0.02--4.50)           10   1.35 (0.11--3.76)     0.368
                   ***P*-value**      0.180                                                                   0.089                0.439                                                          
  Pathology          Adenocarcinoma   66                                                                      1.03 (0.04--2.01)    32      3.10**^∗a^** (2.95--5.72)   22   1.66 (1.01--2.76)     ***0.005***
                     Mucinous         34                                                                      1.72 (0.26--3.01)    16      0.96 (0.07--2.62)           10   1.12 (0.06--4.93)     0.301
                   ***P*-value**      0.263                                                                   ***0.020***          0.340                                                          
  Tumor grade        II               82                                                                      1.03 (0.07--2.95)    34      2.64 (0.42--4.88)           24   1.53 (0.19--3.76)     0.200
                     III              20                                                                      2.06 (0.09--6.15)    14      1.84 (0.34--4.24)           8    1.22 (0.073--3.27)    0.156
                   ***P*-value**      0.386                                                                   0.910                0.628                                                          
  Tumor size         T2               15                                                                      1.94 (0.041--5.47)   12      2.71 (1.81--9.35)           9    2.59 (0.04--2.61)     0.247
                     T3               65                                                                      0.98 (0.04--2.86)    30      2.58 (0.42--4.88)           18   1.59 (1.01--7.64)     0.097
                     T4               19                                                                      1.51 (0.18--2.77)    6       0.62 (0.003--2.87)          5    0.05 (0.001--1.26)    0.472
                   ***P*-value**      0.337                                                                   0.081                0.150                                                          
  Lymph node         Negative         41                                                                      1.01 (0.06--2.77)    26      2.92**^a^** (2.67--4.67)    22   1.19 (0.116--2.17)    ***0.007***
                     Positive         39                                                                      1.51 (0.11--3.61)    22      2.42 (0.03--5.11)           10   3.27 (1.43--7.60)     0.988
                   ***P*-value**      0.343                                                                   0.628                0.055                                                          
  Metastasis         Negative         71                                                                      1.03 (0.04--3.01)    38      2.62**^a^** (0.42--5.33)    24   1.61 (0.73--3.27)     ***0.048***
                     Positive         31                                                                      1.12 (0.10--4.06)    10      1.25 (0.42--4.87)           8    1.43 (0.07--3.76)     0.846
                   ***P*-value**      0.710                                                                   0.608                0.671                                                          
                     II               32                                                                      1.09 (0.03--2.74)    20      3.62**^a^** (2.96--5.22)    13   1.06 (0.15--2.17)     ***0.028***
  Stage              III              39                                                                      0.91 (0.06--3.51)    18      2.62 (0.07--5.39)           11   2.93 (1.35--3.51)     0.717
                     IV               31                                                                      1.12 (0.14--4.06)    10      1.25 (0.42--4.87)           8    1.43 (0.07--3.76)     0.846
                   ***P*-value**      0.755                                                                   0.875                0.115                                                          

Data presented as medians ×
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and interquartile range (IQR) of DNMT3A expression level relative to B- actin (2

-ΔCT

). Significant

P

-values were with bold italic font.

∗

Superscript is a significant difference (

P

-value \< 0.05) when two CRC subgroups was compared by Mann--Whitney.

a

Is a significant difference (

P

-value \< 0.05) when the 3 and 6 months treated patients were compared with their baseline by Wilcoxon Matched. DNMT3A, DNA- methyltransferase 3A; CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; NA, not applicable.

A significant DNMT3B overexpression was seen in patients with mucinous and grade III tumors baseline. FP therapy increased significantly DNMT3B expression in patients with high CA19.9 after 3 months and in patients with negative metastasis and stage II after 6 months of therapy, **Table [4](#T4){ref-type="table"}**.

###### 

DNMT3B gene expression in subgroups of patients at baseline and after treatment with FP therapy.

  Variables                           DNMT3B gene expression relative to B- actin (2^-ΔCT)^ in CRC patients   *P*-value                                                                                   
  ---------------- ------------------ ----------------------------------------------------------------------- --------------------------- ---- -------------------------- ---- -------------------------- -------
  Age                ≤45              47                                                                      0.80 (0.45--11.31)          23   0.57 (0.11--2.04)          15   0.66 (0.48--2.43)          0.236
                     \>45             55                                                                      0.60 (0.15--4.23)           25   0.60 (0.30--2.20)          17   0.66 (0.11--0.90)          0.529
                   ***P*-value**                                                                              0.133                            0.628                           0.245                      
  Sex                Female           47                                                                      0.70 (0.41--10.93)          20   0.30 (0.18--0.86)          13   0.70 (0.59--1.59)          0.236
                     Male             55                                                                      0.64 (0.25--4.23)           28   0.80 (0.37--2.51)          19   0.55 (0.12--1.32)          0.178
                   ***P*-value**                                                                              0.271                            0.092                           0.355                      
  **CEA Level**      Normal           46                                                                      0.62 (0.27--9.92)           5    0.70 (0.21--2.14)          4    0.59 (0.18--0.81)          0.307
                     High             33                                                                      0.50 (0.15--11.24)          13   0.83 (0.10--2.51)          8    1.71 (0.11--1.73)          0.998
                   ***P*-value**                                                                              0.935                            0.503                           0.786                      
  CA19.9 level       Normal           57                                                                      0.70 (0.21--11.31)          2    0.83 (0.48--2.20)          1    0.68 (0.68--0.68)          NA
                     High             15                                                                      0.80 (0.40--20.82)          17   2.51**^∗^** (2.51--4.71)   11   0.62 (0.20--1.59)          0.980
                   ***P*-value**                                                                              0.699                            ***0.010***                     0.794                      
  Tumor location     Right colon      30                                                                      0.80 (0.30--4.23)           15   0.37 (0.11--0.70)          16   0.64 (0.20--0.90)          0.459
                     Left colon       25                                                                      0.30 (0.15--0.87)           15   1.42 (0.20--3.30)          6    1.59 (0.11--24.93)         0.264
                     Rectum           40                                                                      1.29 (0.41--29.05)          18   0.72 (0.36--2.21)          10   0.70 (0.13--1.71)          0.066
                   ***P*-value**                                                                              0.08                             0.379                           0.615                      
  Pathology          Adenocarcinoma   66                                                                      0.60 (0.25--3.10)           32   0.70 (0.15--2.09)          22   0.68 (0.20--0.90)          0.584
                     Mucinous         34                                                                      0.99**^∗^** (0.40--11.24)   16   0.47 (0.26--1.58)          10   0.48 (0.13--5.17)          0.276
                   ***P*-value**                                                                              ***0.020***                      0.899                           0.881                      
  Tumor grade        II               82                                                                      0.66 (0.27--4.44)           34   0.75 (0.30--2.14)          24   0.66 (0.16--1.25)          0.247
                     III              20                                                                      1.39**^∗^** (0.20--11.24)   14   0.39 (0.18--0.60)          8    0.66 (0.48--5.17)          0.819
                   ***P*-value**                                                                              ***0.040***                      0.500                           0.342                      
  Tumor size         T2               15                                                                      0.56 (0.35--6.32)           12   0.49 (0.11--2.14)          9    0.59 (0.20--0.62)          0.717
                     T3               65                                                                      0.80 (0.25--8.06)           30   0.57 (0.30--2.04)          18   0.81 (0.20--1.73)          0.395
                     T4               19                                                                      0.49 (0.15--0.87)           6    0.70 (0.10--4.08)          5    0.18 (0.11--0.70)          0.717
                   ***P*-value**                                                                              0.569                            0.932                           0.243                      
  Lymph node         Negative         41                                                                      0.59 (0.20--0.62)           26   0.30 (0.11--0.80)          22   0.75 (0.40--1.66)          0.441
                     Positive         39                                                                      0.81 (0.20--1.73)           22   0.86 (0.57--2.46)          10   0.48 (0.13--0.81)          0.236
                   ***P*-value**                                                                              0.075                            0.068                           0.319                      
  Metastasis         Negative         71                                                                      0.70 (0.29--4.77)           38   0.60 (0.30--2.04)          24   0.75 (0.48--1.71)          0.465
                     Positive         31                                                                      0.50 (0.19--6.16)           10   0.37 (0.10--2.51)          8    0.11**^∗^** (0.10--0.18)   0.097
                   ***P*-value**                                                                              0.196                            0.456                           ***0.014***                
                     II               32                                                                      0.60 (0.20--3.10)           20   0.30 (0.18--0.80)          13   0.85 (0.59--1.73)          0.641
  Stage              III              39                                                                      1.19 (0.33--9.92)           18   1.41 (0.57--2.46)          11   0.68 (0.31--1.26)          0.368
                     IV               31                                                                      0.50 (0.19--6.16)           10   0.37 (0.10--2.51)          8    0.11**^∗^** (0.10--0.18)   0.097
                   ***P*-value**                                                                              0.271                            0.196                           ***0.037***                

Data presented as medians and interquartile range (IQR) of DNMT3B expression level relative to B- actin (2

-Δ

CT

). Significant

P

-values were with bold italic font.

∗

Superscript is a significant difference (

P

-value \< 0.05) when two CRC subgroups were compared by Mann--Whitney. DNMT3B, DNA- methyltransferase 3B; CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; NA, not applicable.

Univariate Analysis of OS
-------------------------

Kaplan--Meier analysis revealed a significant higher OS in patients with normal initial level of CEA (30.6 versus15.13 months) and CA19.9 (28.22 versus 12.7 months), **Supplementary Figures [S2A,B](#SM1){ref-type="supplementary-material"}**, respectively. Significant improvement in OS was shown in patients with negative metastasis (30.6 versus 12.33 months), **Supplementary Figure [S2C](#SM1){ref-type="supplementary-material"}** and patients in stages II and III (27.46 and 25.23 months versus 12.33 months), **Supplementary Figure [S2D](#SM1){ref-type="supplementary-material"}**.

Moreover, it was noticed that patients with 5mC % ≤8.02 % (8.02 is the median 5mC % in 102 baseline CRC patients) had significant higher median OS (26.07 versus 23.3 months), as shown in **Figure [3A](#F3){ref-type="fig"}**.

![Kaplan--Meier survival curves for CRC patients according to their global DNA methylation levels. **(A)** OS of CRC patients with 5mC% ≤ 8.02 and \>8.02. **(B)** EFS of CRC patients with 5mC level ≤ 0.55 and \>0.55.](fphar-09-01173-g003){#F3}

Univariate Analysis of EFS
--------------------------

There was a significant association of higher median EFS in patients with normal CEA and CA19.9 baseline levels (35.6 versus 14.35 months, for CEA and 23.73 versus 9.1 months, for CA19.9), **Supplementary Figures [S3A,B](#SM1){ref-type="supplementary-material"}**. Also, patients with T3 tumors had significant higher EFS (35.6 months) than those with T4 tumors (19.43 months), **Supplementary Figure [S3C](#SM1){ref-type="supplementary-material"}**. Negative metastatic patients had significant improvement in their EFS (35.6 versus 8.1 months), **Supplementary Figure [S3D](#SM1){ref-type="supplementary-material"}**, as well as patients at stages II and III (30.95 and 24.17 months, respectively versus 16.47 months for patients at stage IV), **Supplementary Figure [S3E](#SM1){ref-type="supplementary-material"}**. Moreover, it was shown that patients with 5mC level \> 0.55 (0.55 is the median 5mC level in 102 baseline CRC patients) had significant higher EFS (22.23 versus18.2 months), **Figure [3B](#F3){ref-type="fig"}**.

Multivariate Analysis of Patients' Survival
-------------------------------------------

Significant increase in the hazard of death and progression were associated CRC patients with high CEA level and positive metastasis, as shown in **Figures [4A,B](#F4){ref-type="fig"}**.

![The multivariate COX regression hazard model. **(A)** Hazard ratio of death and **(B)** progression. Table indicates the hazard ratio and 95% confidence interval, associated with high level of CEA, high level of CA19.9, T4, positive metastasis, stage (IV) and 5mc level \> 0.55. *P*-value \< 0.05 is a significant hazard of death or progression, when hazard ratios of table variables compared with reference variables. **Reference variables (hazard value of 1):** low level of CEA, low level of CA19.9, T2 and T3 tumors, negative metastasis, stages II and III and 5mC level ≤ 0.55. OS, overall survival; EFS, event free survival; CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; 5mC, 5, methoxy 2 deoxy cytosine.](fphar-09-01173-g004){#F4}

Discussion
==========

CRC persists as one of the most prevalent and deadly tumor type in both men and women worldwide, in spite of widespread effective measures of preventive screening and major advances in treatment options ([@B2]). Epigenetics especially DNA methylation is one of the contributing factors to CRC pathogenesis and treatment outcome ([@B36]).

Methylation of the C-5 position of cytosine in genomic DNA is a central mammalian epigenetic control mechanism that affects gene expression ([@B36]). In this study, the change in global DNA methylation in terms of 5mC level and 5mC % at baseline as well as after FP therapy was investigated in the peripheral blood samples. In this work peripheral blood lymphocytes was preferred as a sampling source than the tissue sections of individual tumor because of the epigenetic intratumoral heterogeneity and differences in DNA methylation pattern ([@B34]; [@B21]). In addition, blood-based specimens such DNA extracted from leukocytes are considered as a non-invasive sampling ([@B30]). Moreover, [@B5] found the same level of hypomethylation in DNA of tumor tissue and peripheral blood samples from patients with primary and metastatic tumors. Furthermore, it was shown that DNA methylation signatures in peripheral blood for multiple disease-related genes are strongly linked to mortality outcomes ([@B61]).

In this study, CRC patients at baseline had significant global hypomethylation, in terms of decreased median levels of 5mC and 5mC % compared to healthy control. This hypomethylation of DNA facilitates the aberrant expression of protooncogenes/oncogenes and potentially stimulates tumor cell proliferation ([@B27]). It was suggested that DNA hypomethylation is likely to induce a cascade effect with direct implications in the determination of the progression pathway, and hence the patient's outcome ([@B48]). One of the possible mechanisms for regulation of DNA methylation in cancer is the ischemic/hypoxic condition found in solid tumors. It was found that 5-mC levels altered with hypoxia. It was suggested that hypomethylation occurs via an active process or through lack of maintenance methylation ([@B51]).

In agreement with our results, DNA global hypomethylation was detected in both colonic and leukocyte of patients with CRC ([@B29]; [@B56]). In addition, an increased risk of a number of cancers, including colorectal adenoma was associated with lower level of global methylation in peripheral blood ([@B31]; [@B5]). On contrary, [@B38] reported no evidence of hypomethylation of leukocyte genomic DNA and increased risk of CRC among women. In addition, [@B20] showed insignificant difference in 5mC overall methylation between the cancerous and precancerous tissues of the colon.

Although the state of hypomethylation observed in CRC patients in this study, an overexpression of DNMT3A and DNMT3B genes were observed. It was proposed that DNA hypomethylation occurs with high expression of DNMTs because of the inhibition of *de novo* methylation through DNMT3 and post- translational degradation of the enzymes, via a class of proteins (UHRF1 and UHRF2) that have been frequently overexpressed in cancer and emerged as epigenetic regulators during DNA replication ([@B19]). It was suggested during cancer progression, an increase in DNMTs activity was seen along DNA hypomethylation, reflecting the chromosomal instability, chromosomal rearrangement of the genome ([@B10]). Moreover, DNMTs overexpression by 15-folds were shown in histologically normal mucosa from patients with cancers or benign polyps that can precede to cancers compared to normal colon mucosa from patients without neoplasia, 60 folds increased in the premalignant polyps, and \>200 folds increased in the cancers ([@B12]).

Subgroup analysis and pairwise comparison conducted for CRC patients with similar clinicopathological characters showed that within the hypomethylated CRC patients, significant higher global 5mC level was associated with T2 tumors, negative lymph nodes, and non-metastasis. In agreement, [@B37] indicated that DNA methylation level is negatively associated with T-stage and is significantly reduced with lymph node metastases in CRC patients. These results were in concordance with most of research conducted on global methylation levels either by 5mC or by LINE-1 (a repetitive sequence of CpG islands across the whole genome and considered as surrogate marker for global DNA methylation) in CRC disease ([@B20]; [@B56]). Moreover, there was statistically significant inverse relationship observed between DNA methylation in colon tissue and adenoma risk which was attributed to deregulation of genes expression causing poor tumor differentiation, altered cell cycle regulation and increasing cancer invasiveness ([@B24]).

Also, our patients who were \>45 years showed significant higher median 5mC level. It was hypothesized that 63% clones of normal colon cells were progressively methylated in an age-dependent manner where the CpG island hypermethylation of inflammatory bowel diseases like CRC was supposed to be promoted by aging rather than inflammation ([@B44]). Likely, significant LINE-1 hypomethylation was shown in early onset CRC than late onset ([@B1]).

In the present study, 5mC level was significantly high in patients who had their tumors in the right side of GIT. Our result was in line with [@B57], who found that DNA methylation was gradually decreased from rectum to descending colon, and then increased from descending colon to ascending colon. In addition, it was reported that aberrant DNA methylation is more prominent in proximal compared with distal CRCs ([@B13]). However, [@B1] reported insignificant difference in LINE-1 global methylation between proximal and distal colonic tumors. Contrary to the above, [@B56] observed significant high 5mC level in rectal cancer patients who had lymph node metastasis. The change in the degree of methylation along the GIT was proposed to be due to the differences in the frequencies of key molecular features such as microsatellite instability (MSI), CpG island methylator phenotype (CIMP), BRAF and PIK3CA mutations along the length of the colorectum ([@B57]). In addition to microbiota that influence the immune response and inflammation from the proximal to distal colorectal segments might lead to the progression of colorectal tumors that exhibit LINE-1 hypomethylation ([@B35]).

Our study revealed significant increase in 5mC level in patients with high-grade tumors and also significant DNMT3B overexpression in patients with mucinous and high-grade tumors. In agreement with our data, [@B1] showed that mucinous tumors have ≥ 65 % higher LINE-1 methylation level. Interestingly, overexpression of DNMT3B in CRC mice model (Apc Min/+ mice), enhanced the number of colon tumors approximately two folds and increased the average size of colonic microadenomas, whereas DNMT3A had no effect ([@B32]). Cancer cells have many aberrant transcripts of DNMT3B, which is linked to *E*-cadherin promoter gene methylation and CRC aggressiveness ([@B6]). Moreover, DNMT3B overexpression was frequently associated with LINE-1 hypermethylation, high-grade histology with many features of combined high MSI, CIMP and BRAF V600E mutation and increased KRAS and wild-type p53 expressions ([@B16]).

CRC patients treated with FP therapy, in the current study, showed significant reductions in their global DNA methylation. Global hypomethylation can be attributed to inhibition of one-carbon metabolic intermediates induced by FP therapy leading to imbalance between SAM and *S*- adenosylhomocysteine (SAH), resulting in altering normal DNA methylation patterns ([@B53]). It was suggested global DNA methylation induced by 5-FU was due to the generated reactive oxygen species, up-regulating ten-eleven translocation (TET1) expression and function. TET1 converts 5-mC to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC), finally leading to cytosine ([@B18]). These modified bases may not only serve as intermediates in the DNA demethylation process but may also increase the diversity of the epigenetic states of genomic DNA and acquisition of 5-FU resistance CRC phenotype ([@B23]). Moreover the hypomethylation was due to the formation of a nucleoside analog which may inhibit DNMTs and leads to its degradation causing demethylation ([@B39]) and consequent re-expression of p16 and RASSF1A tumor suppressor genes ([@B7]).

In this study, tumors with good prognostic features and higher 5mC level at baseline show better response to FP therapy. This is not only because of the high intracellular folate concentrations but also because of the silencing of critical genes like DPYD ([@B17]). Moreover, variability in the DNA methylation of colonic mucosa results in different metabolic conversion of 5-FU into its active metabolite fluorouridine monophosphate (FdUMP) and inhibition of TS activity through the misincorporation of FUTP and FdUTP into RNA and DNA, respectively ([@B54]).

5FU induced significant DNA hypomethylation, with significant over expression of DNMT3B after 3 months compared to their levels at baseline. The increase in DNMT3B expression was suggested to be as a compensatory mechanism for the global hypomethylation levels. DNMT3B causes hypermethylation of promoter CpG-rich regions in a variety of malignancies ([@B59]) and repress transcription in either methylation-dependent manner ([@B32]; [@B41]) or through their histone deacetylase activity ([@B15]). Moreover, DNMT3B overexpression was frequently associated with LINE-1 hypermethylation, high-grade histology with many features of combined high MSI, CIMP and BRAF V600E mutation and increased KRAS and wild-type p53 expressions ([@B16]).

In [@B26], it was seen that 5FU enhanced c-MYC activity and induced ATP-binding cassette transporters expression. DNMT3B expression is dependent on oncogenic MYC levels, which is as a site-specific transcription factor regulator for hundreds of genes ([@B46]). Increased DNMT activity is significantly associated with high rates of methylation-dependent gene silencing which contributes to 5FU resistance ([@B49]).

Also, we found that CRC patients with high CA19.9 exhibited significant DNMT3A and DNMT3B overexpression. However, this result is not reliable and could be attributed to chance as the number of CRC patients with normal CA19.9 was two compared to 17 patients with high CA19.9, so that association should be repeated in a larger number of patients.

The bad prognostic behavior of high CA19.9 was seen in our patients' OS and EFS. In this study, CRC patients with high initial CEA and CA19.9 levels faced significant reduction in their OS and EFS times and also had significant increase in the hazards of both death and disease progression. Similarly, it was found that high preoperative CEA level had a negative survival impact regardless of tumor stage and the combination measurement of both tumor markers was suggested to improve the prognostic power of CRC patients' survival ([@B8]).

Adding to the above, patients with tumor sizes T2 and T3 had significant high EFS as well as the early stage of the disease and non- metastatic CRC patients had significant improved OS and EFS. Metastasis caused significant increase in the risk of death (hazard ratio = 1.41, *P* \< 0.001) and disease progression (hazard ratio = 1.43, *P* \< 0.001). In addition, the pathological stage is the most important prognostic factor following surgical resection of colorectal tumors. The prognosis for early stages (I and II) is favorable overall, in contrast to the prognosis for advanced stages (III and IV) ([@B60]).

Our results showed that patients with higher global 5mC level (\>0.55) had improved EFS, while patients with 5mC % (\>8.02) were associated with reduced OS. Similarly, [@B4] found lower 5mC level is correlated with advanced malignancy grade in breast and colon cancer. Improved patients' survival with global hypermethylation levels baseline ([@B22]). In addition, LINE-1 hypermethylation is negatively associated with the T- stage and lymph node metastases in CRC patients ([@B37]). Contrary to the previous studies, in metanalysis study of [@B29] showed that genome-wide hypomethylation have significant desirable effects on the OS of patients with various types of cancers.

[@B56] identified the 5mC ratio between cancers to normal tissues as an independent prognostic factor for patient's outcome, the lower the ratio is, the worse survival becomes. It was proposed that the significant deterioration of EFS with 5mC level ≤ 0.55 has been correlated with genomic instability resulting in the re-expression of proto-oncogenes or imprinted genes, as well as the activation of viral and parasitic transposons. Besides, DNA hypomethylation has been demonstrated to increase the immunogenicity and immune recognition of cancer cells through the up-regulation of different molecules involved in antigen proceeding and presentation ([@B48]).

The normalization of 5mC level to the total pool of cytosines as 5mC % is proposed to be a reflection to the amount and density of methylated CpG It was suggested that there is a coordinated regulation of methylation changes between the 2 types of methylation. [@B27] observed an antagonistic functions of hypo and hyper methylation in the differentiation, cell-cycle regulation and proliferation. Hypomethylation and hypermethylation usually co-exist in the same tumor but in different sequence, it had been proposed that there is cross talk between demethylation and de novo methylation pathways during tumorigenesis, making one dependent on the other ([@B11]). For example, DNA demethylation might be used as a type of epigenetic repair to compensate for physiologically inappropriate methylation of CpG islands overlapping promoters of tumor suppressor genes. It was proposed that DNA hypomethylation might occur early in oncogenesis followed by hypermethylation as a kind of increased, compensatory de novo methylation ([@B45]). However, [@B11] linked hyper- and hypo-methylation of DNA to CRC carcinogenesis in an inter-relationship rather than dependence on each other. Both hypermethylation and hypomethylation of DNA have been observed in most tested cancers but in different sequences. Many specific gene regions become hypermethylated, and some other gene regions and many non-coding DNA repeats become hypomethylated during carcinogenesis ([@B40]).

Conclusion
==========

Egyptian CRC patients had global DNA hypomethylation and DNMT3A and DNMT3B overexpression. FP therapy caused significant hypomethylation particularly in the subgroups of CRC patients with high baseline DNA methylation and good prognostic features. Patients with 5mC % \>8.02% had significant deterioration in OS and significant positive impact in EFS was associated patients with 5mC level \> 0.55. Hazards of death and progression were significantly associated with high initial CEA level and positive metastasis.
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CRC

:   colorectal cancer

DNMT

:   DNA methyl transferase

DPYD
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:   fluorouridine
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